Leerink Partnrs Has Negative Forecast for TVTX Q4 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) - Investment analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research report issued on Wednesday, June 11th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of $0.13 per share for the quarter, down from their prior forecast of $0.17. The consensus estimate for Travere Therapeutics' current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.08. The company had revenue of $81.73 million during the quarter, compared to analysts' expectations of $77.44 million. Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The firm's revenue for the quarter was up 83.3% compared to the same quarter last year. During the same quarter last year, the business posted ($1.76) EPS.

Several other analysts have also commented on the company. Citigroup cut their price objective on Travere Therapeutics from $35.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday. HC Wainwright raised shares of Travere Therapeutics to a "buy" rating and set a $30.00 price objective for the company in a research report on Wednesday. Scotiabank reaffirmed an "outperform" rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Canaccord Genuity Group lifted their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a research note on Thursday, April 10th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.14.

Travere Therapeutics Stock Down 2.9%

Shares of TVTX traded down $0.44 during trading hours on Friday, hitting $14.50. The company had a trading volume of 1,582,706 shares, compared to its average volume of 1,615,272. Travere Therapeutics has a 52-week low of $6.80 and a 52-week high of $25.29. The firm has a fifty day moving average price of $16.87 and a 200-day moving average price of $18.56. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -3.54 and a beta of 0.75. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Hedge Funds Weigh In On Travere Therapeutics

Large investors have recently made changes to their positions in the stock. Summit Investment Advisors Inc. boosted its stake in shares of Travere Therapeutics by 9.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after purchasing an additional 667 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Travere Therapeutics by 4.3% during the 1st quarter. Arizona State Retirement System now owns 23,364 shares of the company's stock valued at $419,000 after buying an additional 968 shares during the period. E Fund Management Co. Ltd. boosted its holdings in Travere Therapeutics by 8.6% in the first quarter. E Fund Management Co. Ltd. now owns 13,553 shares of the company's stock valued at $243,000 after acquiring an additional 1,072 shares during the last quarter. Diversified Trust Co lifted its stake in shares of Travere Therapeutics by 8.6% in the 1st quarter. Diversified Trust Co now owns 15,959 shares of the company's stock valued at $286,000 after purchasing an additional 1,258 shares in the last quarter. Finally, Oak Ridge Investments LLC increased its position in shares of Travere Therapeutics by 2.8% in the first quarter. Oak Ridge Investments LLC now owns 54,070 shares of the company's stock worth $969,000 after acquiring an additional 1,471 shares in the last quarter.

Insider Activity at Travere Therapeutics

In related news, insider Peter Heerma sold 1,771 shares of Travere Therapeutics stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $37,279.55. Following the completion of the transaction, the insider now owns 128,215 shares in the company, valued at $2,698,925.75. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Eric M. Dube sold 18,924 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $21.05, for a total value of $398,350.20. Following the transaction, the chief executive officer now directly owns 419,173 shares in the company, valued at approximately $8,823,591.65. The trade was a 4.32% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,527 shares of company stock worth $473,814. Insiders own 4.19% of the company's stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.